FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

KJ Scanlon

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Disorders

Genes & Molecular Sequences

Concepts & Ideas

Molecular Sequence Data

Procedures

Genetic Therapy

Co-author Network

Publications

TOP 3
Akira Irie; Kazumasa Matsumoto; B Anderegg; Hidetoshi Kuruma; Mohammed Kashani-Sabet; KJ Scanlon; Toyoaki Uchida; Shiro Baba
Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.
T Suzuki; B Anderegg; T Ohkawa; Akira Irie; O Engebraaten; M Halks-Miller; P S Holm; D T Curiel; Mohammed Kashani-Sabet; KJ Scanlon
Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells.
Akira Irie; Mohammed Kashani-Sabet; KJ Scanlon; Toyoaki Uchida; Shiro Baba
Hammerhead ribozymes as therapeutic agents for bladder cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of KJ Scanlon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Akira Irie; Kazumasa Matsumoto; B Anderegg; Hidetoshi Kuruma; Mohammed Kashani-Sabet; KJ Scanlon; Toyoaki Uchida; Shiro Baba
Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.
Cancer gene therapy 2006;13(3):298-305.
2000: T Suzuki; B Anderegg; T Ohkawa; Akira Irie; O Engebraaten; M Halks-Miller; P S Holm; D T Curiel; Mohammed Kashani-Sabet; KJ Scanlon
Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells.
Gene therapy 2000;7(3):241-8.
2000: Akira Irie; Mohammed Kashani-Sabet; KJ Scanlon; Toyoaki Uchida; Shiro Baba
Hammerhead ribozymes as therapeutic agents for bladder cancer.
Molecular urology 2000;4(2):61-6.
1999: Akira Irie; B Anderegg; Mohammed Kashani-Sabet; T Ohkawa; T Suzuki; M Halks-Miller; D T Curiel; KJ Scanlon
Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.
Antisense & nucleic acid drug development 1999;9(4):341-9.
1997: Akira Irie; DY Bouffard; KJ Scanlon
Ribozyme-mediated cancer gene therapy.
International journal of urology : official journal of the Japanese Urological Association 1997;4(4):329-37.
1997: LD Curcio; DY Bouffard; KJ Scanlon
Oligonucleotides as modulators of cancer gene expression.
Pharmacology & therapeutics 1997;74(3):317-32.
1997: Akira Irie; H Kijima; T Ohkawa; DY Bouffard; T Suzuki; LD Curcio; P S Holm; A Sassani; KJ Scanlon
Anti-oncogene ribozymes for cancer gene therapy.
Advances in pharmacology (San Diego, Calif.) 1997;40():207-57.
1996: D Y Bouffard; T Ohkawa; H Kijima; Akira Irie; T Suzuki; LD Curcio; P S Holm; A Sassani; KJ Scanlon
Oligonucleotide modulation of multidrug resistance.
European journal of cancer (Oxford, England : 1990) 1996;32A(6):1010-8.
1996: Y Ohta; H Kijima; T Ohkawa; Mohammed Kashani-Sabet; KJ Scanlon
Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.
Nucleic acids research 1996;24(5):938-42.
1996: Y Ohta; H Kijima; Mohammed Kashani-Sabet; KJ Scanlon
Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes.
The Journal of investigative dermatology 1996;106(2):275-80.
1995: KJ Scanlon; Y Ohta; H Ishida; H Kijima; T Ohkawa; A Kaminski; J Tsai; G Horng; Mohammed Kashani-Sabet
Oligonucleotide-mediated modulation of mammalian gene expression.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1995;9(13):1288-96.
1995: H Kijima; H Ishida; T Ohkawa; Mohammed Kashani-Sabet; KJ Scanlon
Therapeutic applications of ribozymes.
Pharmacology & therapeutics 1995;68(2):247-67.
1994: KJ Scanlon; H Ishida; Mohammed Kashani-Sabet
Ribozyme-mediated reversal of the multidrug-resistant phenotype.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(23):11123-7.
1994: T Funato; T Shitara; T Tone; L Jiao; Mohammed Kashani-Sabet; KJ Scanlon
Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme.
Biochemical pharmacology 1994;48(7):1471-5.
1994: P Taverna; J Hansson; KJ Scanlon; B T Hill
Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
Carcinogenesis 1994;15(9):2053-6.
1994: P S Holm; KJ Scanlon; M Dietel
Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme.
British journal of cancer 1994;70(2):239-43.
1994: Mohammed Kashani-Sabet; T Funato; V A Florenes; O Fodstad; KJ Scanlon
Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
Cancer research 1994;54(4):900-2.
1994: B T Hill; KJ Scanlon; J Hansson; A Harstrick; M Pera; AM Fichtinger-Schepman; S A Shellard
Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.
European journal of cancer (Oxford, England : 1990) 1994;30A(6):832-7.
1993: T Tone; Mohammed Kashani-Sabet; T Funato; T Shitara; E Yoshida; B I Kashfian; M Horng; O Fodstadt; KJ Scanlon
Suppression of EJ cells tumorigenicity.
In vivo (Athens, Greece) 1993;7(6A):471-6.
1993: A Yoshida; V Davé; H Han; KJ Scanlon
Enhanced transcription of the cytosolic ALDH gene in cyclophosphamide resistant human carcinoma cells.
Advances in experimental medicine and biology 1993;328():63-72.
1992: B T Hill; S A Shellard; L K Hosking; W C Dempke; AM Fichtinger-Schepman; T Tone; KJ Scanlon; R D Whelan
Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Cancer research 1992;52(11):3110-8.
1992: T Funato; E Yoshida; L Jiao; T Tone; Mohammed Kashani-Sabet; KJ Scanlon
The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas.
Advances in enzyme regulation 1992;32():195-209.
1992: H Miyachi; L Jiao; Lawrence C Sowers; KJ Scanlon
Collateral sensitivity to azidothymidine in methotrexate resistant human leukemia cells.
In vivo (Athens, Greece) 1992;6(1):17-21.
1991: KJ Scanlon; Mohammed Kashani-Sabet; T Tone; T Funato
Cisplatin resistance in human cancers.
Pharmacology & therapeutics 1991;52(3):385-406.
1991: KJ Scanlon; L Jiao; T Funato; W Wang; T Tone; John J Rossi; Mohammed Kashani-Sabet
Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(23):10591-5.
1991: H Miyachi; H Han; KJ Scanlon
Dihydrofolate reductase gene expression characterized by the PCR assay in human leukemia cells.
In vivo (Athens, Greece) 1991;5(1):7-12.
1990: KJ Scanlon; W Z Wang; H Han
Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells.
Cancer treatment reviews 1990;17 Suppl A():27-35.
1990: Mohammed Kashani-Sabet; W Wang; KJ Scanlon
Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells.
The Journal of biological chemistry 1990;265(19):11285-8.
1990: J Han; L Jiao; Y Lu; Z Sun; Q M Gu; KJ Scanlon
Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent.
In vivo (Athens, Greece) 1990;4(3):153-60.
1990: Nahid F Mivechi; H Miyachi; KJ Scanlon
Heat radiosensitization and the level of DNA polymerases alpha and beta of human colony-forming unit-granulocyte-macrophage and myeloid leukemias sensitive and resistant to chemotherapeutic agents.
Cancer research 1990;50(7):2044-8.
1990: Mohammed Kashani-Sabet; Y Lu; L Leong; K Haedicke; KJ Scanlon
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil.
European journal of cancer (Oxford, England : 1990) 1990;26(3):383-90.
1990: KJ Scanlon; T Funato; B Pezeshki; T Tone; Lawrence C Sowers
Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells.
Cancer communications 1990;2(10):339-43.
1989: KJ Scanlon; Mohammed Kashani-Sabet; H Miyachi; Lawrence C Sowers; J Rossi
Molecular basis of cisplatin resistance in human carcinomas: model systems and patients.
Anticancer research 1989;9(5):1301-12.
1989: KJ Scanlon; Mohammed Kashani-Sabet
Utility of the polymerase chain reaction in detection of gene expression in drug-resistant human tumors.
Journal of clinical laboratory analysis 1989;3(5):323-9.
1989: KJ Scanlon; Mohammed Kashani-Sabet; H Miyachi
Differential gene expression in human cancer cells resistant to cisplatin.
Cancer investigation 1989;7(6):581-7.
1989: KJ Scanlon; Mohammed Kashani-Sabet; Lawrence C Sowers
Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine.
Cancer communications 1989;1(4):269-75.
1988: Mohammed Kashani-Sabet; John J Rossi; Y Lu; J X Ma; J Chen; H Miyachi; KJ Scanlon
Detection of drug resistance in human tumors by in vitro enzymatic amplification.
Cancer research 1988;48(20):5775-8.
1988: Y Lu; J Han; KJ Scanlon
Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid.
The Journal of biological chemistry 1988;263(10):4891-4.
1988: KJ Scanlon; Mohammed Kashani-Sabet
Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(3):650-3.
1988: Edward M Newman; Y Lu; Mohammed Kashani-Sabet; V Kesavan; KJ Scanlon
Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin.
Biochemical pharmacology 1988;37(3):443-7.
1988: KJ Scanlon; Y Lu; Mohammed Kashani-Sabet; J Ma; E Newman
Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo.
Advances in experimental medicine and biology 1988;244():127-35.
1986: KJ Scanlon; Edward M Newman; Y Lu; D G Priest
Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(23):8923-5.
1986: V Kesavan; P Sur; M T Doig; KJ Scanlon; David G Priest
Effects of methotrexate on folates in Krebs ascites and L1210 murine leukemia cells.
Cancer letters 1986;30(1):55-9.